BeiGene | Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

⟵ Back to Search Results

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Beigene Study ID

BGB-A317-309

ClinicalTrials.gov ID

NCT03924986

China Drug Trials ID

CTR20182534

Sex: All

Age: 18 Years / 75 Years

No Study Documents

Sex: All

Age: 18 Years / 75 Years

No Study Documents